Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Announces Expanded Scientific Advisory Board

MarketWire Canada January 19, 2017

12 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  December 27, 2016

Biotech Companies Continue Quest for Advanced Drug Developments

PR Newswire December 13, 2016

Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

MarketWire Canada December 13, 2016

Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2016

MarketWire Canada November 21, 2016

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  November 17, 2016

Biotech Stocks Press Forward with Drug-Development Advancements

PR Newswire November 17, 2016

Moleculin Announces Positive FDA Guidance Regarding Annamycin IND

MarketWire Canada November 17, 2016

Biotech Stocks Advancement of Aggressive Studies and Treatments Playing a Critical Role in Industry Growth

PR Newswire October 26, 2016

16 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  October 21, 2016

Biotech Stocks Worth A Glance Testing Sector Trends

PR Newswire October 20, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  October 11, 2016

A Cascade Of Corporate Exec Hires This Week

Benzinga.com  August 25, 2016

Slingshot Insights Hosts Informative Call On Moleculin Biotech: Here Are The Details

Benzinga.com  June 22, 2016

UPDATE -- Moleculin Biotech, Inc. (Nasdaq: MBRX) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO

GlobeNewswire June 2, 2016